Back to today’s briefing

Story perspectives

FDA Approves Gilead’s Once-Daily Bixlenvo HIV Regimen

8/29/2026

32 5 Full Breakdown

Summary

Story summary

The U.S. Food and Drug Administration approved Gilead Sciences' Bixlenvo, a once-daily single-tablet HIV regimen.
A 30-day supply of Bixlenvo has a wholesale acquisition cost of $4,595.
In ARTISTRY trials, 96% of patients achieved viral suppression at week 48, versus 94% on prior regimens.
Bixlenvo simplifies treatment for virologically suppressed adults without resistance, replacing complex multi-tablet regimens.

1 of 1

Story summary

The U.S. Food and Drug Administration approved Gilead Sciences' Bixlenvo, a once-daily single-tablet HIV regimen.
A 30-day supply of Bixlenvo has a wholesale acquisition cost of $4,595.
In ARTISTRY trials, 96% of patients achieved viral suppression at week 48, versus 94% on prior regimens.
Bixlenvo simplifies treatment for virologically suppressed adults without resistance, replacing complex multi-tablet regimens.